Cancer Vaccines (CPB 0557, reviewed 2025-12-02)
Summary
Cancer vaccines are considered experimental, investigational, or unproven because their safety and effectiveness have not been established. The listed items are the helper multi-peptide (6MHP) vaccine for metastatic melanoma, HLA-A24-binding peptide vaccines for gastric cancer, the melanoma vaccine (also known as Theraccine or Oncophage) for any indication, the p16(INK4a)-based peptide vaccine for human papillomavirus-associated cancers, the p62 DNA vaccine (Elenagen) for solid tumors, and whole cancer stem cell-based vaccines used as an adjuvant strategy for the surgical management of solid tumors. The clinical evidence is stated as not sufficient to permit conclusions on health outcome effects of tumor-associated antigenic peptide-based vaccine therapy for acute myeloid leukemia, breast cancer, central nervous system cancers, colorectal cancer, gallbladder cancer, gastric cancer, glioma, head and neck cancer, hepatic cancer, lung cancer, oral squamous cell carcinoma, ovarian cancer and pancreatic cancer.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.